| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases |
0 |
0 |
0 |
1 |
7 |
9 |
10 |
38 |
| Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective |
0 |
0 |
0 |
1 |
3 |
5 |
6 |
38 |
| Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective |
0 |
0 |
0 |
0 |
4 |
4 |
4 |
4 |
| Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries |
0 |
0 |
0 |
8 |
2 |
4 |
6 |
48 |
| Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries |
0 |
0 |
0 |
7 |
0 |
0 |
2 |
70 |
| Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries |
0 |
0 |
0 |
0 |
5 |
7 |
8 |
9 |
| Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis |
0 |
0 |
0 |
3 |
1 |
4 |
5 |
44 |
| Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis |
0 |
0 |
0 |
0 |
2 |
5 |
6 |
6 |
| Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis |
0 |
0 |
0 |
0 |
1 |
7 |
9 |
12 |
| Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
2 |
| Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres |
0 |
0 |
0 |
5 |
1 |
5 |
7 |
54 |
| Cost-of-illness studies in nine Central and Eastern European countries |
0 |
0 |
0 |
2 |
1 |
5 |
7 |
26 |
| Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS |
0 |
0 |
0 |
1 |
5 |
5 |
7 |
25 |
| Development of an Instrument for the Assessment of Health-Related Multi-sectoral Resource Use in Europe: The PECUNIA RUM |
0 |
0 |
0 |
1 |
5 |
7 |
13 |
26 |
| EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review |
0 |
0 |
1 |
3 |
4 |
6 |
10 |
29 |
| Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
35 |
| Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison |
0 |
0 |
0 |
0 |
2 |
3 |
5 |
5 |
| Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD) |
0 |
0 |
1 |
14 |
0 |
1 |
5 |
83 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary |
0 |
0 |
0 |
4 |
2 |
2 |
4 |
60 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary |
0 |
0 |
0 |
0 |
2 |
3 |
7 |
7 |
| In Search for Comparability: The PECUNIA Reference Unit Costs for Health and Social Care Services in Europe |
0 |
0 |
0 |
0 |
1 |
4 |
7 |
11 |
| Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe? |
0 |
0 |
1 |
5 |
2 |
3 |
6 |
36 |
| Patient and general population values for luminal and perianal fistulising Crohn’s disease health states |
0 |
0 |
0 |
1 |
1 |
2 |
2 |
20 |
| Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary |
0 |
0 |
0 |
0 |
2 |
2 |
2 |
4 |
| Population normative data for OxCAP-MH capability scores |
0 |
0 |
0 |
0 |
0 |
3 |
5 |
5 |
| Psychometric properties and general population reference values for PROMIS Global Health in Hungary |
0 |
0 |
0 |
0 |
2 |
4 |
4 |
5 |
| Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary |
0 |
0 |
0 |
0 |
2 |
2 |
4 |
9 |
| Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries? |
0 |
0 |
0 |
2 |
6 |
9 |
12 |
22 |
| Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe |
0 |
0 |
0 |
3 |
3 |
4 |
5 |
39 |
| Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe |
0 |
0 |
1 |
4 |
0 |
1 |
2 |
47 |
| Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary |
0 |
0 |
0 |
0 |
2 |
4 |
5 |
19 |
| Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists |
0 |
0 |
0 |
0 |
3 |
5 |
7 |
7 |
| Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists |
0 |
0 |
0 |
3 |
2 |
5 |
5 |
37 |
| Subjective well-being in patients with pemphigus: a path analysis |
0 |
0 |
0 |
1 |
2 |
6 |
7 |
27 |
| The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
6 |
| The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease |
0 |
0 |
0 |
0 |
4 |
4 |
5 |
5 |
| The disease burden of colorectal cancer in Hungary |
0 |
0 |
0 |
23 |
0 |
0 |
1 |
133 |
| The impact of the recession on health care expenditure — How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries? |
0 |
0 |
0 |
8 |
1 |
1 |
2 |
46 |
| Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
15 |
| Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries |
0 |
0 |
0 |
0 |
1 |
4 |
6 |
6 |
| Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries |
0 |
0 |
0 |
0 |
2 |
2 |
2 |
26 |
| Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary |
0 |
0 |
0 |
3 |
3 |
4 |
9 |
81 |
| Value Set for the EQ-5D-Y-3L in Hungary |
0 |
0 |
0 |
3 |
1 |
1 |
2 |
8 |
| Total Journal Articles |
0 |
0 |
4 |
109 |
89 |
154 |
231 |
1,235 |
LogEc is hosted by the
Örebro University School of Business.